ACHE and astrocytoma (excluding glioblastoma): These include: 1) the relationship of human astrocytoma aggressiveness and altered patterns of splice-derived AChE variants [34]; 2) the increased labelling of cytoplasm-residing AChE in ovarian cancer [38]; 3) the shorter DFS and OS rates of patients carrying low AChE activity-exhibiting hepatocarcinoma [23]; and 4) the low ChE activity assayed in specimens of advanced prostate cancer [39].